BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28447249)

  • 1. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
    Harada H
    Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1.
    Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA
    Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
    Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
    Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].
    Shirane S; Araki M; Morishita S; Edahiro Y; Ohsaka A; Komatsu N
    Rinsho Ketsueki; 2015 Jul; 56(7):877-82. PubMed ID: 26251152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
    Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
    Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of genetic data to clinical practice of MPN].
    Edahiro Y
    Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wong WJ; Hasserjian RP; Pinkus GS; Breyfogle LJ; Mullally A; Pozdnyakova O
    Haematologica; 2018 Feb; 103(2):e63-e68. PubMed ID: 29146710
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
    Mansier O; Luque Paz D; Ianotto JC; Le Bris Y; Chauveau A; Boyer F; Conejero C; Fitoussi O; Riou J; Adiko D; Touati M; Chauzeix J; Viallard JF; Béné MC; Giraudier S; Ugo V; Lippert E
    Am J Hematol; 2018 Aug; 93(4):E84-E86. PubMed ID: 29266414
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular genetics of MDS/MPN overlap syndromes.
    Hunter AM; Padron E
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis with co-mutated JAK2 and SF3B1.
    Reinig EF; He R
    Blood; 2017 Feb; 129(5):656. PubMed ID: 28153838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.